What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?
What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe? Value Health. 2014 Nov; 17(7):A636.